
Catherijne Aj Knibbe

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/10545649/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Impact of Obesity on Drug Metabolism and Elimination in Adults and Children. Clinical Pharmacokinetics, 2012, 51, 277-304.	1.6	288
2	Morphine Glucuronidation in Preterm Neonates, Infants and Children Younger than 3 Years. Clinical Pharmacokinetics, 2009, 48, 371-385.	1.6	129
3	Body Weight-Dependent Pharmacokinetics of Busulfan in Paediatric Haematopoietic Stem Cell Transplantation Patients. Clinical Pharmacokinetics, 2012, 51, 331-345.	1.6	115
4	Association between Busulfan Exposure and Outcome in Children Receiving Intravenous Busulfan before Hematologic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2009, 15, 231-241.	2.0	107
5	Immune Reconstitution Kinetics as an Early Predictor for Mortality using Various Hematopoietic Stem Cell Sources in Children. Biology of Blood and Marrow Transplantation, 2013, 19, 305-313.	2.0	99
6	Population Pharmacokinetics and Pharmacodynamics of Propofol in Morbidly Obese Patients. Clinical Pharmacokinetics, 2011, 50, 739-750.	1.6	65
7	Prediction of Propofol Clearance in Children from an Allometric Model Developed in Rats, Children and Adults versus a 0.75 Fixed-Exponent Allometric Model. Clinical Pharmacokinetics, 2010, 49, 269-275.	1.6	61
8	Risk factors for chronic thoracic pain after cardiac surgery via sternotomy. European Journal of Cardio-thoracic Surgery, 2011, 40, 1309-13.	0.6	52
9	Predictive Performance of a Recently Developed Population Pharmacokinetic Model for Morphine and its Metabolites in New Datasets of (Preterm) Neonates, Infants and Children. Clinical Pharmacokinetics, 2011, 50, 51-63.	1.6	51
10	Predictive Performance of a Busulfan Pharmacokinetic Model in Children and Young Adults. Therapeutic Drug Monitoring, 2012, 34, 574-583.	1.0	48
11	Individualized dosing regimens in children based on population PKPD modelling: Are we ready for it?. International Journal of Pharmaceutics, 2011, 415, 9-14.	2.6	46
12	Critical Illness Is a Major Determinant of Midazolam Clearance in Children Aged 1 Month to 17 Years. Therapeutic Drug Monitoring, 2012, 34, 381-389.	1.0	43
13	Population pharmacokinetics of paracetamol across the human ageâ€range from (pre)term neonates, infants, children to adults. Journal of Clinical Pharmacology, 2014, 54, 619-629.	1.0	42
14	Advances in paediatric pharmacokinetics. Expert Opinion on Drug Metabolism and Toxicology, 2011, 7, 1-8.	1.5	39
15	Evidence-based drug treatment for special patient populations through model-based approaches. European Journal of Pharmaceutical Sciences, 2017, 109, S22-S26.	1.9	37
16	Population pharmacokinetics of vancomycin in obesity: Finding the optimal dose for (morbidly) obese individuals. British Journal of Clinical Pharmacology, 2020, 86, 303-317.	1.1	37
17	Paracetamol and morphine for infant and neonatal pain; still a long way to go?. Expert Review of Clinical Pharmacology, 2017, 10, 111-126.	1.3	23
18	Drug Dosing in Obese Children. Pediatric Clinics of North America, 2017, 64, 1417-1438.	0.9	16

#	Article	IF	CITATIONS
19	An Update on the Use of Allometric and Other Scaling Methods to Scale Drug Clearance in Children: Towards Decision Tables. Expert Opinion on Drug Metabolism and Toxicology, 2022, 18, 99-113.	1.5	10
20	ls indirect hyperbilirubinemia a useful biomarker of reduced propofol clearance in neonates?. Biomarkers in Medicine, 2012, 6, 283-289.	0.6	8
21	Short- and long-term impact of remifentanil on thermal detection and pain thresholds after cardiac surgery. European Journal of Anaesthesiology, 2019, 36, 32-39.	0.7	6
22	Remifentanil versus fentanyl during cardiac surgery on the incidence of chronic thoracic pain (REFLECT): study protocol for a randomized controlled trial. Trials, 2014, 15, 466.	0.7	5
23	Quantifying the Pharmacodynamics of Morphine in the Treatment of Postoperative Pain in Preverbal Children. Journal of Clinical Pharmacology, 2022, 62, 99-109.	1.0	3